IGM Biosciences (IGMS) Competitors $1.38 +0.08 (+5.73%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IGMS vs. TRDA, ARCT, TSHA, HRTX, ATYR, ATAI, PVLA, AURA, CYRX, and GLUEShould you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Entrada Therapeutics (TRDA), Arcturus Therapeutics (ARCT), Taysha Gene Therapies (TSHA), Heron Therapeutics (HRTX), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. IGM Biosciences vs. Entrada Therapeutics Arcturus Therapeutics Taysha Gene Therapies Heron Therapeutics Atyr PHARMA Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Entrada Therapeutics (NASDAQ:TRDA) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Which has preferable valuation & earnings, TRDA or IGMS? Entrada Therapeutics has higher revenue and earnings than IGM Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M1.64-$6.68M$1.914.78IGM Biosciences$2.68M30.90-$246.42M-$3.24-0.43 Is TRDA or IGMS more profitable? Entrada Therapeutics has a net margin of 25.53% compared to IGM Biosciences' net margin of -7,534.03%. Entrada Therapeutics' return on equity of 16.11% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics25.53% 16.11% 10.39% IGM Biosciences -7,534.03%-155.42%-61.04% Do insiders and institutionals have more ownership in TRDA or IGMS? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in TRDA or IGMS? IGM Biosciences received 51 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.00% of users gave Entrada Therapeutics an outperform vote while only 47.68% of users gave IGM Biosciences an outperform vote. CompanyUnderperformOutperformEntrada TherapeuticsOutperform Votes2184.00% Underperform Votes416.00%IGM BiosciencesOutperform Votes7247.68% Underperform Votes7952.32% Does the media refer more to TRDA or IGMS? In the previous week, Entrada Therapeutics and Entrada Therapeutics both had 2 articles in the media. IGM Biosciences' average media sentiment score of 0.62 beat Entrada Therapeutics' score of 0.53 indicating that IGM Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IGM Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, TRDA or IGMS? Entrada Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Do analysts rate TRDA or IGMS? Entrada Therapeutics presently has a consensus price target of $25.67, suggesting a potential upside of 181.12%. IGM Biosciences has a consensus price target of $5.50, suggesting a potential upside of 297.11%. Given IGM Biosciences' higher possible upside, analysts clearly believe IGM Biosciences is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90 SummaryEntrada Therapeutics beats IGM Biosciences on 12 of the 18 factors compared between the two stocks. Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IGMS vs. The Competition Export to ExcelMetricIGM BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.79M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.387.4422.4818.48Price / Sales30.90242.70394.56103.59Price / CashN/A65.8538.1834.62Price / Book0.406.516.774.25Net Income-$246.42M$143.21M$3.22B$248.23M7 Day Performance0.36%1.98%1.48%0.89%1 Month Performance20.43%6.89%3.99%3.53%1 Year Performance-85.39%-2.52%16.15%5.08% IGM Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IGMSIGM Biosciences4.3356 of 5 stars$1.39+5.7%$5.50+297.1%-85.6%$82.79M$2.68M-0.38190Upcoming EarningsNews CoverageTRDAEntrada Therapeutics2.8762 of 5 stars$7.95-2.2%$25.67+222.9%-23.0%$298.88M$210.78M5.00110Upcoming EarningsNews CoverageHigh Trading VolumeARCTArcturus Therapeutics2.9829 of 5 stars$11.00+4.5%$59.20+438.2%-49.9%$298.32M$138.39M-4.95180News CoveragePositive NewsGap DownTSHATaysha Gene Therapies2.1385 of 5 stars$1.45+16.9%$6.63+356.9%-20.2%$297.33M$8.33M2.30180Analyst ForecastNews CoverageGap DownHRTXHeron Therapeutics3.7183 of 5 stars$1.93+4.9%$5.67+193.6%+4.3%$294.00M$144.29M-10.72300Upcoming EarningsNews CoveragePositive NewsGap UpATYRAtyr PHARMA2.3959 of 5 stars$3.28+5.8%$18.60+467.1%N/A$291.46M$235,000.00-3.4953Short Interest ↑News CoverageATAIAtai Life Sciences2.6737 of 5 stars$1.42-3.4%$10.50+639.4%-24.2%$283.69M$308,000.00-1.7580Positive NewsPVLAPalvella Therapeutics3.4225 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastHigh Trading VolumeAURAAura Biosciences2.3414 of 5 stars$5.57+3.9%$22.75+308.4%-21.2%$279.75MN/A-3.2250Upcoming EarningsShort Interest ↑Positive NewsGap DownCYRXCryoport2.3918 of 5 stars$5.52-0.5%$11.67+111.4%-65.5%$275.50M$228.39M-1.631,020Gap DownGLUEMonte Rosa Therapeutics1.9756 of 5 stars$4.46-2.0%$15.50+247.5%-7.7%$274.34M$75.62M-2.4490Upcoming EarningsShort Interest ↑News Coverage Related Companies and Tools Related Companies TRDA Alternatives ARCT Alternatives TSHA Alternatives HRTX Alternatives ATYR Alternatives ATAI Alternatives PVLA Alternatives AURA Alternatives CYRX Alternatives GLUE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IGMS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IGMS Stock Free IGMS Stock Alerts